HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing

The financing delivered $3.0 million at closing; access to another $7.0 million remains conditional.

Rhea-AI Summary

HCW Biologics (HCWB) closed debt financing on November 4, 2026, securing access to up to $10.0 million in cash.

The financing provided $3.0 million at closing, with another $7.0 million subject to certain conditions. The company intends to fund clinical and operating activities needed to complete its dose-escalating Phase 1 study of HCW9302 as a stand-alone treatment for alopecia areata. HCW Biologics expects to establish the Recommended Phase 2 Dose in the first quarter of 2027.

3 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point$3.0 million in cash received at the November 4, 2026 debt-financing closing. 1.2× market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Financing supports planned completion of the HCW9302 Phase 1 study in alopecia areata.
• Moderate point. Forward-looking: it has not happened yet and may not happen.HCW Biologics expects to establish the Recommended Phase 2 Dose in the first quarter of 2027.

Negative

• Major pointDebt financing adds borrowing obligations for HCW Biologics.
• Minor pointAccess to $7.0 million in additional funds is subject to certain conditions.

News Explained

HCW Biologics closed the debt financing on November 4, 2026, receiving $3.0 million and conditional access to another $7.0 million; its June 30, 2026 balance sheet showed $741,324 cash and $4,854,028 in long-term investments, equal to 128.4 days of second-quarter operating cash use at that quarter’s rate.

Sources and calculations

• HCW Biologics financing press release (2026-11-05)
• HCW Biologics 2026 second-quarter fundamentals (2026-06-30)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate ($741,324 + $4,854,028) / ($3,966,138 / 91) = 128.4 days

Argus 15 min delay 2 alerts

+1.91% vs previous close $1.10 last price 5.3x rel. volume Open Argus

Details

Market Reaction – HCWB

$1.09 – $1.16 Day Range

$2.46M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for HCWB is 1.91% above the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $1.10. Relative volume is exceptionally heavy at 5.3x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Financing capacity: Up to $10.0 million Funding at closing: $3.0 million Additional financing: $7.0 million +1 more

Financing capacity

Up to $10.0 million

Debt financing to fund clinical and operating activities

Funding at closing

$3.0 million

Provided upon closing on November 4, 2026

Additional financing

$7.0 million

Access subject to certain conditions

Expected dose milestone

First quarter of 2027

Expected establishment of the Recommended Phase 2 Dose for HCW9302

Key Terms

debt financing, alopecia areata, monotherapy, recommended phase 2 dose

4 terms

debt financing financial

"the Company closed on a debt financing"

Debt financing is the process of raising money by borrowing it from lenders, which must be paid back over time with interest. It is like taking a loan to fund a project or investment, allowing a business or individual to access funds immediately while agreeing to repay the amount borrowed later. For investors, understanding debt financing helps assess how a company funds its operations and manages financial risk.

alopecia areata medical

"HCW9302 as a monotherapy for the treatment of alopecia areata"

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, causing round patches of hair loss on the scalp or body; severity ranges from small spots to widespread baldness. Investors watch it because successful treatments, clinical trial results, regulatory approvals, or shifts in prevalence can create or shrink markets for drugs and therapies, affecting the value of companies developing remedies—think of it as demand risk and regulatory risk for hair-loss products.

monotherapy medical

"HCW9302 as a monotherapy for the treatment of alopecia areata"

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

recommended phase 2 dose medical

"establishing the Recommended Phase 2 Dose which is expected"

Recommended phase 2 dose is the specific drug amount chosen after initial human studies to use in mid-stage clinical trials that assess whether the treatment works and remains reasonably safe in patients. Investors pay attention because that dose determines how convincing the upcoming trial results are likely to be, influences the size, cost and duration of further studies, and affects the chance of regulatory approval and commercial success—much like picking the right test speed to judge a new car's performance without risking damage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose

MIRAMAR, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for treatments of autoimmune diseases, cancer, and senescence-associated dysplasia, today announced that the Company secured up to $10.0 million in cash to fund the clinical and operating activities necessary to complete the dose-escalating Phase 1 study evaluating HCW9302 as a monotherapy for the treatment of alopecia areata and establishing the Recommended Phase 2 Dose which is expected in the first quarter of 2027. On November 4, 2026, the Company closed on a debt financing, which provided $3.0 million upon closing and access to $7.0 million in additional funds, subject to certain conditions.

About HCW Biologics:

HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics for the treatment of diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. HCW Biologics is the leader in creation of multivalent immunotherapeutics with a unique protein-based scaffold, without the antibody Fc domain. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs, including its commercial-ready reagents to be used in the production of immunotherapeutics for cancer and infectious diseases. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/

Forward Looking Statements:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, successfully completing Phase 1 study to evaluate HCW9302 in alopecia areata; timing of a Phase 1 readout for the HCW9302 study in the first quarter of 2027; completing of the dosing of four dose-escalating cohorts by the first quarter of 2027; results of the evaluations of HCW9302 in the Phase 1 study including dose-limiting toxicities; whether the funding secured will be adequate to reach the Phase 1 readout for the HCW9302 study. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 31, 2026 and in other filings filed from time to time with the SEC.

Company Contact:

Rebecca Byam
Chief Financing Officer
HCW Biologics Inc.
RebeccaByam@hcwbiologics.com

This press release was published by a CLEAR® Verified individual.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much funding did HCW Biologics secure through its November 2026 debt financing?

HCW Biologics secured access to up to $10.0 million, including $3.0 million received at closing on November 4, 2026. Access to the additional $7.0 million is subject to certain conditions.

What will HCW Biologics fund with the debt financing?

The financing is intended to fund clinical and operating activities needed to complete the HCW9302 Phase 1 study in alopecia areata and establish the Recommended Phase 2 Dose. The company expects to establish that dose in the first quarter of 2027.